These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31113590)

  • 1. Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals.
    Pariente A; Arpurt JP; Remy AJ; Rosa-Hezode I; Causse X; Heluwaert F; Macaigne G; Henrion J; Renou C; Schnee M; Salloum H; Hommel S; Pilette C; Arotcarena R; Barjonet G; Lison H; Bourhis F; Jouannaud V; Pauwels A; Le-Bricquir Y; Geagea E; Condat B; Ripault MP; Zanditenas D; de Montigny-Lenhardt S; Labadie H; Tissot B; Maringe E; Cadranel JF; Hagege H; Lesgourgues B;
    Ann Hepatol; 2019; 18(1):193-202. PubMed ID: 31113590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
    Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
    Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
    J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
    Beck KR; Kim N; Khalili M
    Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Gayam V; Tiongson B; Khalid M; Mandal AK; Mukhtar O; Gill A; Garlapati P; Shrestha B; Khalid M; Chakraborty S; Guss D; Sherigar J; Mansour M; Mohanty S
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1200-1207. PubMed ID: 30096090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
    Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil.
    Holzmann I; Tovo CV; Minmé R; Leal MP; Kliemann MP; Ubirajara C; Aquino AA; Araujo B; Almeida PRL
    Braz J Infect Dis; 2018; 22(4):317-322. PubMed ID: 30036490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
    Nagral A; Jhaveri A; Sawant S; Parikh NS; Nagral N; Merchant R; Gandhi M
    Indian J Pediatr; 2019 Feb; 86(2):148-153. PubMed ID: 30097845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 May; 36(5):651-8. PubMed ID: 26616353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.
    Trabut JB; Barrault C; Charlot H; Carmona D; Bourdel A; Benslimane M; François M; Kini-Matondo W; Causse R; Roudot-Thoraval F; Hézode C
    J Addict Med; 2018; 12(5):346-352. PubMed ID: 29702515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
    Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
    Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).
    Pariente A; Arpurt JP; Rémy AJ; Rosa-Hézode I; Causse X; Heluwaert F; Macaigne G; Henrion J; Renou C; Schnee M; Salloum H; Hommel S; Pilette C; Arotcarena R; Barjonet G; Lison H; Bourhis F; Jouannaud V; Pauwels A; Le eaBricquir Y; Geagea E; Condat B; Ripault MP; Zanditenas D; de Montigny-Lenhardt S; Labadie H; Tissot B; Maringe E; Cadranel JF; Hagège H; Lesgourgues B;
    Presse Med; 2019 Mar; 48(3 Pt 1):e101-e110. PubMed ID: 30853287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.